KOSDAQBiotech & Pharma228760

Genomictree

₩8,430▲ 0.84%2026-11-18 close
Market Cap
₩209.6B
Turnover
₩300M
Volume
30K
Shares out.
24.9M
PER
—
PBR
1.9×
EPS
-₩365
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Genomictree: Revenue Rebounds, Losses Persist

Revenue rose 59.2% in 2025, yet operating losses have continued for three straight years, and the company has reported losses for five consecutive quarters through Q3 2026. The keys to a profit turn are reimbursement for its Early-Tec tests in Korea and the start of sales at its China joint venture.

  1. 1

    2025 revenue of KRW 3.76 billion rose 59.2% from the 2024 low, but the operating loss of KRW 11.3 billion remains large.

  2. 2

    Q3 2026 revenue of KRW 758 million fell 15.4% year on year, and the first three quarters of 2026 add up to about KRW 1.98 billion.

  3. 3

    Early-Tec C is currently not reimbursed, so its evaluation under Korea's new medical technology review and insurance listing are the key variables for market expansion.

  4. 4

    Under its China license structure, the company is due a KRW 1 billion milestone tied to manufacturing approval and royalties linked to sales.

  5. 5

    Debt-to-equity stood at 4.7% at end-2025 with total equity of KRW 115.3 billion, a low leverage profile, yet operating cash flow has been negative from 2023 through 2025.

02

Business structure

Genomictree is an in-vitro molecular diagnostics company that analyzes cancer-related genetic changes in body fluids.

Its flagship Early-Tec C test detects methylation of the SDC2 gene in stool to support colorectal cancer diagnosis, and since its Korean approval in 2018 and launch in 2019 the company has emphasized 90.2 percent sensitivity and results within eight hours.

Early-Tec B, a non-invasive colorectal test, received final sales approval from the Korean food and drug regulator, and Leading Investment & Securities said the product has now entered the market in earnest.

The bladder cancer product received Class 3 approval in January 2026, and the pipeline also includes lung and prostate cancer products.

Domestic service revenue dominates the mix: according to a local outlet quoting a regional newspaper, domestic service revenue was KRW 3.2 hundred million in Q1 2026, or 83.9 percent of the total.

Overseas, a China joint venture with Shandong Lukang and Orion Holdings, formed under a 2021 agreement, handles clinical work, approvals, manufacturing and sales of the colorectal test.

Genomictree receives stage-based technology fees and royalties tied to sales, and at signing its CEO highlighted royalty income without associated production cost. Overseas sales of Early-Tec C are expected through EDX Medical, according to Leading Investment & Securities in an April 2026 report.

Key customers are screening centers, primary care clinics and the joint venture partner, and revenue combines domestic testing services with overseas technology licensing income.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩900M-₩3.4B−384.0%
2025Q4₩800M-₩2.6B−317.5%
2026Q1₩400M-₩3B−793.9%
2026Q2₩800M-₩2.6B−313.9%
2026Q3₩800M-₩2.7B−362.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩29.9B₩2.4B-₩6.6B8.1%−6.2%51.5%
2023₩3.4B-₩17.3B-₩8.8B−506.2%−7.0%6.2%
2024₩2.4B-₩15.3B-₩10.2B−648.2%−8.3%5.1%
2025₩3.8B-₩11.3B-₩9B−300.5%−7.8%4.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed annual basis, revenue fell from KRW 29.9 billion in 2022 to KRW 3.42 billion in 2023 (down 88.6% year on year), then to KRW 2.36 billion in 2024 (down 30.9%), before recovering to KRW 3.76 billion in 2025 (up 59.2%). The largest year in 2022-2025 was 2022, and the smallest was 2024.

Operating income of KRW 2.41 billion in 2022 turned into an operating loss of KRW 17.3 billion in 2023, and the loss narrowed to KRW 15.3 billion in 2024 and KRW 11.3 billion in 2025. The operating margin moved from 8.1 percent in 2022 to -506.2 percent in 2023, -648.2 percent in 2024 and -300.5 percent in 2025.

The 2023 swing to a loss reflected an operating loss that grew while revenue fell 88.6 percent. What drove the 2022 revenue level cannot be determined from the disclosed figures alone.

Given that the China licensing deal combines upfront payments, stage-based fees and sales-linked royalties, the timing of fee recognition could make annual revenue volatile.

Net loss attributable to controlling shareholders was KRW 6.63 billion in 2022, KRW 8.76 billion in 2023, KRW 10.2 billion in 2024 and KRW 8.99 billion in 2025. Net loss including non-controlling interests, a different figure, was KRW 9.01 billion in 2023, KRW 10.4 billion in 2024 and KRW 9.13 billion in 2025.

By quarter, the operating loss narrowed from KRW 3.44 billion in Q3 2025 to KRW 2.62 billion in Q4 2025, then widened to KRW 3.03 billion in Q1 2026 on revenue of KRW 382 million, down 53.8 percent from the prior quarter.

Revenue rebounded to KRW 842 million in Q2 2026, up 120.7 percent quarter on quarter, and Q3 2026 revenue of KRW 758 million fell 15.4 percent year on year with an operating loss of KRW 2.75 billion.

The company has posted losses for five consecutive quarters from Q3 2025 through Q3 2026, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 8.91 billion.

Against the KRW 7.1 billion revenue estimate that Leading Investment & Securities gave in April 2026, the first three quarters of 2026 add up to roughly KRW 1.98 billion, a wide gap. Operating cash flow was KRW -10.9 billion in 2023, KRW -13.6 billion in 2024 and KRW -10.2 billion in 2025.

At end-2025, total equity was KRW 115.3 billion, equity attributable to controlling shareholders was KRW 115.1 billion and total liabilities were KRW 5.45 billion, with debt-to-equity falling from 51.5 percent in 2022 to 4.7 percent in 2025.

05

Industry analysis

Colorectal cancer screening is moving toward non-invasive stool tests that complement invasive endoscopy. Leading Investment & Securities judged in an April 2026 report that Early-Tec B, as a non-invasive test, is likely to see stronger demand than Early-Tec C.

In a 2020 report, the company said colorectal cancer kills about 280,000 people a year in China and that endoscopy equipment penetration in medical institutions is around 35 percent.

In the same report, the company estimated the Chinese early colorectal diagnostics market at about KRW 13 trillion for 2022, which is its own estimate. On competition, Early-Tec C delivers results within eight hours, compared with the 26 hours cited for Cologuard in the U.S.

As Early-Tec C is not yet reimbursed in Korea, insurance listing will determine how fast adoption spreads, and it competes with existing colorectal screening methods.

At the stage of the cycle, Early-Tec B is in full commercial rollout after approval, Early-Tec C is under the new medical technology review, and China is at the stage after manufacturing approval and before sales start.

Unlike listed peers such as Samsung Biologics and Celltrion, which center on biologics manufacturing or therapeutics, Genomictree's revenue base rests on in-vitro diagnostics and technology licensing royalties.

At the 2021 signing, the company described it as the first patented technology licensing-out deal in liquid-biopsy-based early cancer detection in Korea.

06

Outlook

The 2026 agenda rests on three pillars: domestic sales growth for Early-Tec B, the medical technology review and insurance listing for Early-Tec C, and the start of sales at the China joint venture.

Leading Investment & Securities described 2026 as the start of a high-growth phase and estimated revenue at KRW 7.1 billion, while expecting operating losses to persist in the same April 2026 report, and it did not disclose an investment rating or target price.

The same brokerage said Early-Tec C is awaiting China's regulatory approval, after which additional earnings upside could be possible.

On the China side, the KRW 1 billion milestone tied to manufacturing approval is expected once pilot production and additional conditions are met, and the company said in an early-November 2026 report that it expects sales to start at the joint venture no later than the first half of 2027.

As of a May 2026 report, Early-Tec C was in the medical technology review stage with insurance listing being pursued. The bladder cancer test received Korean approval and CE-IVDR certification in January 2026, which supports overseas expansion.

For full-year 2026 revenue to reach the KRW 7.1 billion estimate, Q4 revenue would have to rise sharply from the first three quarters, which totaled about KRW 1.98 billion, and this is the next point to watch.

In the 2026 annual report, the scale of improvement in the operating margin from -300.5 percent in 2025 will be the key checkpoint. Whether royalties from China sales begin will also change the annual revenue mix.

Changes in capital structure, including treasury share disposals and the convertible bond cancellation, should also be read as facts in judging per-share value.

07

Valuation

PER
—
PBR
1.9×
ROE
-7.7%
EPS
-₩365
BPS
₩4,679
Dividend per share
₩0

Price-to-book sits at a premium to net asset value attributable to controlling shareholders, meaning the share price trades above book equity. The price-to-earnings ratio cannot be calculated because the last four quarters show net losses, so earnings-based comparison is not possible.

On a dividend-yield basis there is little dividend income to compare with industry peers. Over several years the company moved from an operating profit in 2022 to operating losses from 2023, and the loss narrowed in 2025, but no quarterly earnings recovery has yet appeared.

In a sector where a premium to net assets is large, the central interpretive question is how far the share price already reflects expectations for sales growth and reimbursement decisions.

Total equity of KRW 115.3 billion and a 4.7 percent debt-to-equity ratio mean the balance sheet carries low leverage even while loss-making. Compared with listed biopharma peers that are profitable, the absence of an earnings-based multiple is the most important difference in how this valuation should be read.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Early-Tec B approval opens a demand path

Leading Investment & Securities judged in an April 2026 report that Early-Tec B, a non-invasive test that has received final sales approval, is likely to build strong demand. The same report said cooperation with screening centers is already underway and primary clinics will be approached through a contract partner.

Domestic service revenue of KRW 320 million in Q1 2026, or 83.9 percent of the total, provides a starting base for domestic testing demand.

Milestones and royalties from the China structure

The 2021 technology transfer, worth KRW 6 billion in total, places clinical work, approvals, manufacturing and sales with the joint venture, while Genomictree receives stage-based fees and royalties linked to sales.

The KRW 1 billion milestone tied to manufacturing approval is expected after pilot production and additional conditions are met. If local sales exceed contract targets, additional milestones would also be triggered.

If the company's expectation of sales starting by the first half of 2027 is met, royalty-based revenue would begin.

Capital housekeeping and a more independent board

Total liabilities were KRW 5.45 billion at end-2025, with debt-to-equity at 4.7 percent and total equity of KRW 115.3 billion. In February 2026 the company disclosed a decision to acquire and cancel its first convertible bond before maturity.

In March 2026 three outside directors were newly appointed, raising the outside-director ratio from 33.33 percent to 66.67 percent.

09

Bear factors

Five straight loss quarters and volatile quarterly sales

The company has reported losses for five consecutive quarters from Q3 2025 through Q3 2026, and net loss attributable to controlling shareholders over the last four quarters totals KRW 8.91 billion.

Q3 2026 revenue of KRW 758 million fell 15.4 percent year on year, and Q1 2026 revenue of KRW 382 million was down 53.8 percent from the prior quarter. With the KRW 7.1 billion estimate far above the roughly KRW 1.98 billion booked in the first three quarters, the scale of Q4 revenue growth is the test.

Early-Tec C is unreimbursed with an uncertain timeline

Early-Tec C is currently not reimbursed, and evaluation under Korea's new medical technology review and insurance listing are cited as the key variables for market expansion. As of a May 2026 report, it was in the review stage, and approval from China's regulator is still pending.

Without a set decision date for reimbursement, the pace of domestic adoption and the scale of overseas sales are hard to gauge.

Operating cash outflows continue

Total equity of KRW 115.3 billion is large, but revenue is concentrated in the Early-Tec colorectal tests, so an approval or reimbursement delay for a single product weighs on the entire result. Even though the 2025 operating loss of KRW 11.3 billion narrowed, the cash outflow remains substantial.

10

Risk factors

Regulatory and reimbursement risk

The outcome of the medical technology review for Early-Tec C and its insurance listing have no fixed timing. If reimbursement decisions are delayed, adoption in the non-reimbursed market stays constrained. Regulatory timelines, including China's approval and the U.S. FDA, remain a precondition for additional overseas revenue.

Dependence on the China partner

Chinese revenue and milestones depend on the joint venture executing approvals, production and sales. If the sales start the company expects for the first half of 2027 slips, revenue recognition would also be delayed. Royalties track sales, so they can swing widely with local market size and the partner's commercial execution.

Cash burn and earnings volatility

Negative operating cash flow has continued since 2023, and quarterly revenue since Q3 2025 has moved between KRW 380 million and KRW 900 million. Quarterly revenue can swing sharply depending on when technology fee income is recognized.

The effects of treasury share disposals for RSU payouts and the convertible bond cancellation on the capital structure also need to be tracked.

11

What to watch next

  1. Around mid-March 2027 (expected)

    The 2026 annual report will fix full-year revenue, operating results and operating cash flow. The timing is projected from last year's annual report, filed on March 18, 2026, and Q4 2026 revenue will be compared with the full-year estimate.

  2. Before the first half of 2027 (company expectation)

    Watch whether the China joint venture starts selling the colorectal test and whether the KRW 1 billion manufacturing-approval milestone is received. Sales-linked royalties and any additional milestones would change the revenue structure.

  3. Timing not yet set

    The result of the medical technology review for Early-Tec C and whether it is listed for insurance reimbursement. Reimbursement status is the main event that would change the pace of domestic adoption and revenue structure.

  4. Around mid-May 2027 (expected)

    The Q1 2027 quarterly report will show the recovery against Q1 2026 revenue of KRW 382 million and an operating loss of KRW 3.03 billion. The timing is projected from last year's Q1 report, filed on May 15, 2026.

12

Overall view

Genomictree's 2025 revenue rose 59.2 percent from the 2024 low, but operating losses of KRW 11.3 billion and net losses attributable to controlling shareholders of KRW 8.99 billion persist.

The company has reported five consecutive quarterly losses through Q3 2026, and Q3 2026 revenue of KRW 758 million fell 15.4 percent year on year. On the balance sheet, debt-to-equity at 4.7 percent and total equity of KRW 115.3 billion indicate a light burden, yet operating cash flow has been negative since 2023.

Bullish factors include final sales approval for Early-Tec B, expected overseas sales for Early-Tec C, and royalty and milestone income from the China structure.

Bearish factors include Early-Tec C remaining unreimbursed with an uncertain timeline, and quarterly revenue in 2026 running well behind the brokerage estimate.

The valuation sits at a premium to net assets with no earnings-based multiple, so how much the share price already reflects expected sales growth is the central question.

The next checkpoints are the 2026 annual operating results and Q4 revenue, China sales start in the first half of 2027, and the Early-Tec C medical technology review outcome.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. mt.co.kr
  2. news.nate.com
  3. m.irgo.co.kr
  4. m.news.nate.com
  5. openbizdata.com
  6. investing.com
  7. m.news.nate.com
  8. m.news.nate.com
  9. stockvery.com
  10. hankyung.com
  11. etoday.co.kr
  12. hellodd.com
  13. econovill.com
  14. edaily.co.kr
  15. etoday.co.kr
  16. medigatenews.com
  17. yakup.com
  18. ncbi.nlm.nih.gov

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis